ERBB2 and breast cancer: In contrast to other anti-HER2 agents, the unique clinical benefits of T-Dxd in HER2-low BC might be achieved by the so-called “bystander killing” mechanisms due to the highly membrane-permeable payload, high drug-to-antibody ratio and cleavable linker.